AbbVie (ABBV) Stock Gains After Completing $21 Billion Pharmacyclics Purchase

NEW YORK (TheStreet) -- AbbVie shares are up 1.99% to $66.78 in afternoon trading on Tuesday after the pharmaceutical company completed its $21 billion buyout of Pharmacyclics  .The deal will add Pharmacyclics' blood cancer treatment Imbruvica to Abbvie's drug portfolio which already features the world's top selling drug Humira. The closing of the deal comes after the company ended its $55 billion tax inversion bid for U.K.-based Shire Pharmaceuticals  earlier this year."The companies' shar...